Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.

Abstract:

:An antidepressant for use in the patient receiving concomitant drug treatment, over-the-counter medications, or herbal products should lack cytochrome P-450 (CYP) 3A4 inductive or inhibitory activity to provide the least likelihood of a drug-drug interaction. This study addresses the potential of 4 diverse antidepressants (venlafaxine, nefazodone, sertraline, and fluoxetine) to inhibit or induce CYP3A4. In a 4-way crossover design, 16 subjects received clinically relevant doses of venlafaxine, nefazodone, or sertraline for 8 days or fluoxetine for 11 days. Treatments were separated by a 7- to 14-day washout period and fluoxetine was always the last antidepressant taken. CYP3A4 activity was evaluated for each subject at baseline and following each antidepressant using the erythromycin breath test (EBT) and by the pharmacokinetics of alprazolam (ALPZ) after 2-mg dose of oral ALPZ. Compared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metabolism (P > 0.05). For nefazodone, a statistically significant inhibition was observed (P < 0.0005). Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline. No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested. These results demonstrate in vivo that, unlike nefazodone, venlafaxine, sertraline, and fluoxetine do not possess significant metabolic inductive or inhibitory effects on CYP3A4.

journal_name

J Clin Psychopharmacol

authors

DeVane CL,Donovan JL,Liston HL,Markowitz JS,Cheng KT,Risch SC,Willard L

doi

10.1097/01.jcp.0000104908.75206.26

subject

Has Abstract

pub_date

2004-02-01 00:00:00

pages

4-10

issue

1

eissn

0271-0749

issn

1533-712X

journal_volume

24

pub_type

临床试验,杂志文章,随机对照试验
  • Fluoxetine: activating and sedating effects at multiple fixed doses.

    abstract::Serotonin uptake inhibitors are generally considered activating antidepressants. To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of maj...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Beasley CM Jr,Sayler ME,Weiss AM,Potvin JH

    更新日期:1992-10-01 00:00:00

  • Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder.

    abstract::Twenty-one women with generalized anxiety disorder (GAD) participated in a 6-week, double-blind, placebo-controlled trial to assess the treatment and abrupt withdrawal effects of diazepam on psychic and somatic symptoms of anxiety. The results confirmed those of previous studies reporting that (1) clinical doses of di...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199606000-00002

    authors: Pourmotabbed T,Mcleod DR,Hoehn-Saric R,Hipsley P,Greenblatt DJ

    更新日期:1996-06-01 00:00:00

  • Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study.

    abstract:BACKGROUND:Second-generation antipsychotics (SGAs) are commonly used to treat children with mental health conditions (MHCs) but are associated with adverse effects including obesity, hypertension, dyslipidemia, and type 2 diabetes. The mechanisms underlying these complications are unknown, but it has been suggested tha...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000956

    authors: Ngai YF,Devlin AM,Panagiotopoulos C

    更新日期:2018-12-01 00:00:00

  • Malpractice and tardive dyskinesia: a conceptual dilemma.

    abstract::This discussion focuses on three basic areas relevant to tardive dyskinesia (TD). The first area includes an overview of some specific acts of negligence that have been the basis for successful malpractice cases involving TD. Some of these acts of negligence include inappropriate assessment of the patient, failure to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-198808001-00014

    authors: Tancredi LR

    更新日期:1988-08-01 00:00:00

  • Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine.

    abstract::There have been many attempts to find predictors of the therapeutic response to the clomipramine treatment of obsessive-compulsive disorder. The majority of studies have failed to identify such predictors. Possible reasons for this failure include the small sample size of most studies, samples homogeneous with respect...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Ackerman DL,Greenland S,Bystritsky A,Morgenstern H,Katz RJ

    更新日期:1994-08-01 00:00:00

  • Phencyclidine and violence: clinical and legal issues.

    abstract::Phencyclidine (PCP) abuse has diminished since PCP's intrusion into American culture in the late 1970s. One of its legacies is the assumption that it provokes violent behavior in humans with predictable regularity. This assumption is so accepted that ingestion of the drug both accidentally and knowingly prior to commi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Brecher M,Wang BW,Wong H,Morgan JP

    更新日期:1988-12-01 00:00:00

  • Persistence of fluphenazine in plasma after decanoate withdrawal.

    abstract::We discontinued fluphenazine decanoate using a double-blind, crossover random order design, in 12 recent onset clinically stable schizophrenics who had been given fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks for at least 1 year prior to drug withdrawal. Each condition (drug or placebo) lasted 12 weeks....

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gitlin MJ,Midha KK,Fogelson D,Nuechterlein K

    更新日期:1988-02-01 00:00:00

  • Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorders research.

    abstract::Phenomenological, physiological, biochemical, and receptor binding measures are useful as dependent variables in affective disorders research. Abnormalities of these measures can result from up-regulation and supersensitivity of cholinergic systems and disturbances of cholinergic-monoaminergic interaction. These devia...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Dilsaver SC

    更新日期:1986-04-01 00:00:00

  • Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.

    abstract::We examined kinetic and dynamic factors to determine the pharmacological and behavioral safety and tolerability of low versus high doses of an opiate antagonist, naltrexone (50 mg/day vs. 100 mg/day), and acamprosate (2 g/day vs. 3 g/day), a functional N-methyl-D-aspartate receptor antagonist, both independently and c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000084029.22282.bb

    authors: Johnson BA,O'Malley SS,Ciraulo DA,Roache JD,Chambers RA,Sarid-Segal O,Couper D

    更新日期:2003-06-01 00:00:00

  • Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among Finnish community-dwelling persons with Alzheimer disease.

    abstract::Concomitant use of acetylcholine esterase inhibitors (AChEIs) and anticholinergic drugs, such as urinary antispasmodics (UA), is generally considered as inappropriate because of their opposite pharmacological actions. However, prevalence and the duration or factors associated with concomitant use have not been previou...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000218

    authors: Torvinen-Kiiskinen S,Taipale H,Tanskanen A,Tiihonen J,Hartikainen S

    更新日期:2014-12-01 00:00:00

  • Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.

    abstract::This investigation aimed to provide evidence on the lack of pharmacokinetic interaction of paroxetine (20 mg/d) and alprazolam (1 mg/d) in combined therapy. In addition, the central effects of both drugs when administered alone and in combination were assessed to rule out any relevant synergistic depressant central ef...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000125689.05091.c6

    authors: Calvo G,García-Gea C,Luque A,Morte A,Dal-Ré R,Barbanoj M

    更新日期:2004-06-01 00:00:00

  • The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs.

    abstract::The clinician using neuroleptic drugs for the treatment of psychotic patients must face a number of questions regarding whether and how to use anticholinergic drugs when extrapyramidal side effects appear. This article explores some of these questions, suggests how they might best be answered, reviews the studies whic...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: McEvoy JP

    更新日期:1983-10-01 00:00:00

  • Effects of third trimester fluoxetine exposure on the newborn.

    abstract::Prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third tri...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199512000-00005

    authors: Goldstein DJ

    更新日期:1995-12-01 00:00:00

  • Mania after withdrawal of isocarboxazid.

    abstract::Two cases of mania following the discontinuation of treatment with isocarboxazid are described. Although this phenomenon has been reported by several investigators to occur after cessation of tricyclic antidepressant therapy, there exists only one isolated report of hypomania after discontinuation of monoamine oxidase...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Rothschild AJ

    更新日期:1985-12-01 00:00:00

  • Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.

    abstract::Results of previous studies on the safety of antidepressants during pregnancy have been conflicting. The primary objective of this study was to investigate whether first-trimester exposure to antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs), was associated with increased risk of congenital...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182490eaf

    authors: Nordeng H,van Gelder MM,Spigset O,Koren G,Einarson A,Eberhard-Gran M

    更新日期:2012-04-01 00:00:00

  • DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers.

    abstract::Hyperprolactinemia mediated by antagonism of dopaminergic neurotransmission in the pituitary gland is a common adverse effect of antipsychotics. Recent studies have suggested that polymorphisms of dopamine receptors can affect the therapeutic response to antipsychotics. Thus, our aim was to evaluate whether 2 such pol...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31822cfff2

    authors: López-Rodríguez R,Román M,Novalbos J,Pelegrina ML,Ochoa D,Abad-Santos F

    更新日期:2011-10-01 00:00:00

  • Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy.

    abstract::In this 6-week, open-label trial, combat veterans meeting DSM-IV criteria for posttraumatic stress disorder (PTSD) were treated with the atypical antipsychotic quetiapine. The starting dose was 25 mg at bedtime with subsequent titration based on tolerability and clinical response. Primary outcome was measured using th...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200302000-00003

    authors: Hamner MB,Deitsch SE,Brodrick PS,Ulmer HG,Lorberbaum JP

    更新日期:2003-02-01 00:00:00

  • Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.

    abstract::This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000177546.34799.af

    authors: de Leon J,Susce MT,Pan RM,Koch WH,Wedlund PJ

    更新日期:2005-10-01 00:00:00

  • Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects.

    abstract::The study presented here compared the acute performance-impairing, subject-rated, and observer-rated effects of quazepam (15, 30, and 45 mg), triazolam (0.1875, 0.375, and 0.5625 mg), zolpidem (7.5, 15, and 22.5 mg), and placebo in nine healthy, non-drug-abusing humans. Quazepam, a trifluoroethylbenzodiazepine, was ch...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199804000-00008

    authors: Rush CR,Armstrong DL,Ali JA,Pazzaglia PJ

    更新日期:1998-04-01 00:00:00

  • The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients.

    abstract:OBJECTIVES:To determine if prolactin levels are associated with glucose-insulin homeostasis in antipsychotic-treated patients with schizophrenia. METHOD:Prolactin levels and glucose homeostasis (quantified using oral glucose tolerance testing, insulin measurement, and homeostasis model assessment) were measured in 15 ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000239791.91330.48

    authors: Howes OD,Smith S,Gaughran FP,Amiel SA,Murray RM,Pilowsky LS

    更新日期:2006-12-01 00:00:00

  • Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.

    abstract::Aripiprazole is widely used to treat schizophrenia. Plasma levels of aripiprazole and its active metabolite dehydroaripiprazole and their clinical responses in patients were explored. Forty-five (male/female: 19/26) patients with schizophrenia were treated with aripiprazole after a washout period of at least 3 days. T...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e3182356255

    authors: Lin SK,Chen CK,Liu YL

    更新日期:2011-12-01 00:00:00

  • Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.

    abstract:CONTEXT:Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder. OBJECTIVE:To evaluate duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on improvement of emotional and painful phy...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.jcp.0000132448.65972.d9

    authors: Goldstein DJ,Lu Y,Detke MJ,Wiltse C,Mallinckrodt C,Demitrack MA

    更新日期:2004-08-01 00:00:00

  • An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder.

    abstract:BACKGROUND:Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response. METHODS:We c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0000000000000764

    authors: Singh V,Arnold JG,Prihoda TJ,Martinez M,Bowden CL

    更新日期:2017-10-01 00:00:00

  • Role of newer medications for bipolar disorder.

    abstract::The quest for additional effective therapies for bipolar study commenced in the 1960s, even before regulatory approval of lithium. This was driven by the recognition that patient response to lithium varied from excellent to poor; thus, significant numbers of patients faced its frequent adverse effects and risks withou...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199604001-00006

    authors: Bowden CL

    更新日期:1996-04-01 00:00:00

  • 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.

    abstract:BACKGROUND:Pathological gambling (PG) is a relatively common and highly disabling impulse control disorder. A range of psychotherapeutic agents including selective serotonin reuptake inhibitors, antiepileptic drugs, and opioid antagonists are shown to be effective in the short-term treatment of PG. The use of a wide ra...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/jcp.0b013e31815a4400

    authors: Dannon PN,Lowengrub K,Musin E,Gonopolsky Y,Kotler M

    更新日期:2007-12-01 00:00:00

  • Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.

    abstract::Olanzapine is an atypical antipsychotic effective in the treatment of schizophrenic patients. After a 2- to 9-day placebo lead-in, 79 inpatients with schizophrenia according to DSM-III-R criteria were placed on an olanzapine dosage of 10 mg/day or 1 mg/day for up to 6 weeks. Blood samples were obtained weekly during t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00004714-199712000-00006

    authors: Perry PJ,Sanger T,Beasley C

    更新日期:1997-12-01 00:00:00

  • The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression.

    abstract:BACKGROUND:Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical exp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000636

    authors: Kelly T,Lieberman DZ

    更新日期:2017-02-01 00:00:00

  • Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.

    abstract::Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged. At the time of follow-up, half of the patients were medication free, e...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nagy LM,Krystal JH,Charney DS,Merikangas KR,Woods SW

    更新日期:1993-02-01 00:00:00

  • An open clinical trial of fluoxetine in the treatment of premature ejaculation.

    abstract::There have been an increased number of recent reports on orgasm-related sexual dysfunction coincident with selective serotonin reuptake inhibitor (SSRI) treatment. In contrast, it has also been reported that SSRIs improve sexual dysfunction. Low doses of clomipramine and paroxetine, potent 5-hydroxytryptamine reuptake...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199610000-00006

    authors: Lee HS,Song DH,Kim CH,Choi HK

    更新日期:1996-10-01 00:00:00

  • Clozapine Titration for People in Early Psychosis: A Chart Review and Treatment Guideline.

    abstract:PURPOSE/BACKGROUND:The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000860

    authors: Ballon JS,Ashfaq H,Noordsy DL

    更新日期:2018-06-01 00:00:00